This article was originally published in The Gray Sheet
Executive SummaryRegisters with the Securities and Exchange Commission a proposed offering of 816,227 shares of common stock and 50,475 shares of Series A preferred stock. All proceeds of the offering will be realized by the selling shareholders, who include present and former Mediq executives and directors.
You may also be interested in...
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.